What is Qvella?
Qvella is dedicated to transforming healthcare by drastically reducing the time and cost associated with diagnosing infectious diseases, ultimately aiming to save lives. The company's proprietary FAST technology employs a novel sample treatment technique that enables the swift isolation, concentration, and detection of infectious agents directly from a blood sample. This timely diagnostic capability is crucial for enabling prompt clinical decisions, leading to improved patient outcomes, shorter hospital stays, reduced side effect profiles, and substantial cost savings in treatment. Founded in 2009 and headquartered in Richmond Hill, Ontario, Qvella operates within the critical MedTech and diagnostics sector.
How much funding has Qvella raised?
Qvella has raised a total of $39.7M across 2 funding rounds:
Series A
$20M
Series B
$19.7M
Series A (2015): $20M, investors not publicly disclosed
Series B (2017): $19.7M led by bioMérieux, Whitecap Venture Partners, RA Capital Advisors, Hatteras Ventures, and Sands Capital
Key Investors in Qvella
bioMérieux
bioMerieux is a French multinational company specializing in in vitro diagnostics, developing and manufacturing innovative solutions for detecting infectious diseases. They provide instruments, reagents, software, and services to clinical laboratories and healthcare professionals.
Hatteras Ventures
Hatteras Venture Partners is a venture capital firm focused on building transformative companies in the biotech, MedTech, and HealthTech sectors, partnering with founders to invest in innovative healthcare solutions.
RA Capital Advisors
RA Capital is an investment bank focused on assisting private companies, particularly first-time sellers, aiming to maximize transaction value and optimize terms through personalized service and due diligence expertise.
What's next for Qvella?
With its recent major strategic investment, Qvella is poised for accelerated growth and market penetration. The substantial capital infusion is expected to fuel further development of its FAST technology, expand its commercial reach, and potentially explore new applications in infectious disease diagnostics. The company's focus on improving patient outcomes and reducing healthcare costs aligns with global health priorities, positioning Qvella for significant impact and continued investor backing as it scales its operations and brings its life-saving technology to a wider market.
See full Qvella company page
